Progress on baculovirus-derived influenza vaccines

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 1, 2008, Pages 56-61

  Cox, M M J ^a  

^a Protein Sciences Corp   (United States)

Author keywords

Baculovirus; Hemagglutinin; Influenza; Insect cells; M2 antigen; Neuraminidase; Vaccine

Indexed keywords

FLUBLOK; HEMAGGLUTININ; INFLUENZA VACCINE; NUCLEOCAPSID PROTEIN; NUCLEOPROTEIN; SIALIDASE; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BACULOVIRUS; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFLUENZA; NONHUMAN; REVIEW;

ANIMALS; BACULOVIRIDAE; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; VACCINES, DNA; VIRAL PROTEINS; VIRION;

HEXAPODA; ORTHOMYXOVIRIDAE;

EID: 38649140512     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Glezen WP: Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev (1982) 4:25-44.
2. Centers for Disease Control: ACIP. Prevention and control of influenza, recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report (MMWR) (2002) 51:1-31. • An important paper that provides information on influenza, including immunization recommendations and uptake.
3. Kida H, Webster RG, Yanagawa R: Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virology (1983) 76(2):91-99.
4. Yoden S, Kida H, Kuwabara M, Yanagawa R, Webster RG: Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Research (1986) 4(3):251-264.
5. Lamb RA: Genes and proteins of the influenza viruses. In: The Influenza Viruses. Krug RM (Ed), Plenum Press, New York, NY, USA (1989):1-87.
6. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr, Ogra PL: Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin I. Studies in human vaccinees. J Immunol (1987) 138(9):3010-3013.
7. Murphy BR, Kasel JA, Chanock RM: Association of serum antineuraminidase antibody with resistance to influenza in man. N Engl J Med (1972) 286(25):1329-1332.
8. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH: The molecular basis of the specific anti-influenza action of amantadine. EMBO J (1985) 4(11):3021-3024.
9. Lamb RA, Krug RM: Orthomyxoviridae: The viruses and their replication. In: Fields Virology. 4th Edition. Knipe DM, Howley PM (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (1996):1487-1531.
10. Pinto LH, Holsinger LJ, Lamb RA: Influenza virus M2 protein has ion channel activity. Cell (1992) 69(3):517-528.
11. Sugrue RJ, Hay AJ: Structural characteristics of the M2 protein of influenza A viruses: Evidence that it forms a tetrameric channel. Virology (1991) 180(2):617-624.
12. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG: Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol (1991) 65(10):5491-5498.
13. Zebedee SL, Lamb RA: Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol (1988) 62(8):2762-2772.
14. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR: Passively transferred monoclonal antibodies to the M2 protein inhibits influenza A virus replication in mice. J Virol (1990) 64(3):1375-1377.
15. Latham T, Galarza JM: Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol (2001) 75(13):6154-6165.
16. Heimpel A, Thomas ED, Adams JR, Smith LJ: The presence of nuclear polyhedrosis virus of Trichoplusia ni on cabbage from the market shelf. Environ Ent (1973) 2(1):72-76.
17. Tinsley TW, Harrap KA: Viruses of invertebrates. In: Comprehensive Virology. Fraenkel-Conrat H, Wagner RR (Eds), Plenum Press, NY, USA (1978) 12:1-101.
18. Kost TA, Condreay JP, Jarvis DL: Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol (2005) 23(5):567-575.
19. Smith GE, Summer MD, Fraser MJ: Production of human β interferon in insect cells infected with a baculovirus expression vector. Mol Cell Biol (1983) 3(12):2156-2165.
20. Miller LK: A virus vector for genetic engineering in invertebrates. In: Genetic Engineering in the Plant Sciences. Panopaulus NJ (Ed), Praeger Publishers, New York, NY, USA (1981):203-222.
21. Lakey DL, Treanor JJ, Betts RF, Smith GE, Thompson J, Sannella E, Reed G, Wilkinson BE, Wright PF: Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis (1996) 174(4):838-841.
22. Powers DC, Smith GE, Anderson EL, Kennedy DJ, Hackett CS, Wilkinson BE, Volvovitz F, Belshe RB, Treanor JJ: Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults. J Infect Dis (1995) 171(6):1595-1599.
23. Powers DC, McElhaney JE, Florendo OA Jr, Manning MC, Upshaw CM, Bentley DW, Wilkinson BW: Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J Infect Dis (1997) 175(2):342-351.
24. Treanor JJ, Betts RF, Smith GE, Anderson EL, Hackett CS, Wilkinson BE, Belshe RB, Powers DC: Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis (1996) 173(6):1467-1470.
25. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine (2001) 19(13-14):1732-1737. •• The first paper to describe clinical trial data of a potential pandemic vaccine candidate.
26. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis (2006) 193(9):1223-1228. • The first paper to describe the safety and immunogenicity of up to 9-fold higher doses of recombinant HA in vulnerable elderly individuals.
27. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP et al: Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: A double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis (2006) 194(10):1394-1397. • The first study to demonstrate improved vaccine response in lymphoma patients vaccinated with high HA doses.
28. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M: Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial. J Am Med Assoc (2007) 297(14):1577-1582. •• This study showed that rHA alone is sufficient to prevent cell-culture confirmed influenza against drifted strains.
29. Holtz, KM, Anderson DK, Cox MM: Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J (2003) (Sept/Oct):65-73.
30. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM: Expression and purification of an influenza hemagglutinin - one step closer to a recombinant protein-based influenza vaccine. Vaccine (2006) 24(12):2176-2185.
31. Cox MM, Anderson DK: Production of a novel influenza vaccine using insect cells: Protection against drifted strains. Influenza Respiratory Viruses (2007) 1(1):35-40. •• A review which summarizes the development progress of FluBlok and the cross-protection provided by rHA.
32. Keitel WA, Couch RB, Cate TR, Hess KR, Baxter B, Quarles JM, Atmar RL, Six HR: High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol (1994) 32(10):2468-2473.
33. Keitel WA, Cate TR, Atmar RL, Turner CS, Kino D, Dukes CM, Six HR, Couch RB: Increased doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol (1996) 3(5):507-510.
34. Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, Limlamthong 34. Y, Fenner BJ, Spencer L, Kwang J: Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture. BMC Microbiol (2006) 6:16.
35. Yang DG, Chung YC, Lai YK, Lai CW, Liu HJ, Hu YC: Avian influenza virus hemagglutinin display on baculovirus envelope: Cytoplasmic domain affects virus properties and vaccine potential. Mol Ther (2007) 15(9):1736.
36. Deroo T, Jou WM, Fiers W: Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine (1996) 14(6):561-569.
37. Johansson BE, Price PM, Kilbourne ED: Immunogenicity of influenza virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine (1995) 13(9):841-845.
38. Kilbourne ED, Pokorny BA, Johansson B, Brett I, Milev Y, Matthews JT: Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis (2004) 189(3):459-461.
39. Matthews J: Preclinical and clinical evaluation of a purified, baculovirus-expressed influenza neuraminidase antigen. The Baculovirus and Insect Cell Culture Conference, San Antonio, TX, USA (2000): Oral presentation.
40. Sylte MJ, Hubby B, Suarez DL: Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine (2007) 25(19):3763-3772.
41. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ: Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine (1995) 13(15):1399- 1402.
42. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP: Antibody responses of the M2 protein of influenza A virus expressed in insect cells. J Gen Virol (1993) 74(1):143-146.
43. Cox MM: Cell-based protein vaccines for influenza. Curr Opin Mol Ther (2005) 7(1):24-29. • An overview of alternative cell culture methods used to produce live influenza viruses.
44. Safdar A, Cox MM: Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Investig Drugs (2007) 16(7):927-934. •• A review on baculovirus-produced influenza vaccines with a medical focus.
45. NIAID launches expanded flu web site for the media: National Institutes of Health, Bethesda, MD, USA (2007). http://www3.niaid.nih.gov/ healthscience/healthtopics/Flu/Research/ongoingResearch/Prevention/oneVaccine. htm
46. Gómez-Puertas P, Albo C, Pérez-Pastrana E, Vivo A, Portela A: Influenza virus matrix protein is the major driving force in virus budding. J Virol (2000) 74(24):11538-11547.
47. Galarza JM, Latham T, Cupo A: Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol (2005) 18(2):365-372.
48. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G: Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine (2005) 23(50):5751-5759.
49. Prel A, Le Gall-Reculé G, Cherbonnel M, Grasland B, Amelot M, Jestin V: Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Dis (2007) 51 (1 Suppl):484-489.
50. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G et al: Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine (2007) 25(19):3871-3878.
51. Quan FS, Huang C, Compans RW, Kang SM: Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 81(7):3514-3524. • This study described the importance of VLP structure in protective immunity.
52. NCT00519389: A phase I/IIa trial to evaluate the safety, reactogenicity, and immunogenicity of an H5N1 virus-like particle (VLP) influenza vaccine (recombinant). National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00519389?term= NCT00519389&rank=1
53. Matassov D, Cupo A, Galarza JM: A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol (2007) 20(3): 441-452.
54. Fiers W, Neirynck S, Deroo T, Saelens X, Jou WM: 54. Soluble recombinant influenza vaccines. Philos Trans R Soc Lond B Biol Sci (2001) 356(1416):1961-1963.
55. NCT00336453: Safety and immunogenicity of FluBlok in 55. pediatrics. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00336453?term= Protein+Sciences+Corporation&rank=4
56. NCT00395174: Comparison of the immunogenicity, safety and reactogenicity of FluBlok, to a licensed vaccine in elderly adults. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ ct2/show/NCT00395174? term=PSC03&rank=1
57. NCT00539981: Immunogenicity, safety, reactogenicity, efficacy, effectiveness and lot consistency of FluBlok. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00539981? term=NCT00539981&rank=1
58. NCT00539864: Safety and reactogenicity of FluBlok and comparison of immunogenicity, efficacy and effectiveness against TIV. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/ NCT00539864?term=NCT00539864&rank=1